Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy

Psychiatry and Clinical Neurosciences

Volumn 51, Issue 4, 1997, Pages 253-257

  Morinobu, Shigeru ^a,d   Tanaka, Takeshi ^a   Kawakatsu, Shinobu ^a   Totsuka, Shiro ^a   Koyama, Eriko ^b   Chiba, Kan ^b   Ishizaki, Takashi ^b   Kubota, Takahiro ^c  

^a YAMAGATA UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c SRL INC   (Japan)

^d NONE   (Japan)

Author keywords

CYP2C19; Depression; Imipramine; N demethylation; S mephenytoin

Indexed keywords

2 HYDROXYDESIPRAMINE; 2 HYDROXYIMIPRAMINE; DESIPRAMINE; DNA; FLUNITRAZEPAM; IMIPRAMINE; MEPHENYTOIN;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; DEMETHYLATION; DEPRESSION; DRUG BLOOD LEVEL; EXON; FEMALE; GENE; GENE MUTATION; GENOTYPE; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; INSOMNIA; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0030872484     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1997.tb02593.x     Document Type: Article

References (33)

1. Küper A, Preisig R. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 1984; 26: 753-759.
2. Nakamura K, Goto F, Ray WA et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 1985 38: 402-408.
3. Wilkinson GR, Guengerich JP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 1989; 43: 53-76.
4. Andersson T, Regaårdh CG, Dahl-Puustinen, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 1990; 12: 415-416.
5. Sindrup SHK, Brosen K, Hansen MG, Aaes Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 1993; 13: 11-17.
6. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther. 1989; 45: 72-79.
7. Koyama E, Tanaka T, Chiba K, Nakamura K, Meyer UA, Goldstein JA. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J. Clin. Psychopharmacol. 1996; 16: 286-293.
8. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1994; 46: 594-598.
9. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major gene-tic defect responsible for the polymorphism of S-mephenytoin metabolism in human. J. Biol. Chem. 1994; 269: 15 419-15 422.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised 3rd edn. American Psychiatric Association, Washington, DC, 1987.
11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiat. 1960; 23: 56-62.
12. Horai Y, Nakano M, Ishizaki T et al. Metoprolol and mephenytoin oxidation polymorphisms in far eastern oriental subjects: Japanese vs. mainland China. Clin. Pharmacol. Ther. 1989; 46: 198-207.
13. m2 in exon 4, in Japanese subjects. Clin. Pharmacol. Ther. 1996; 59: 647-653.
14. Lingjaerde O, Ahlfos VG, Bech P, Danker SJ, Elgen K. The UKU side effects rating scale. Acta. Psychiatr. Scan. 1987; 76(Suppl.): S81-S92.
15. Koyama E, Kikuchi Y, Echizen H, Chiba K, Ishizaki T. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylate metabolites and imipramine N-oxide in human plasma and urine: Preliminary application to oxidation pharmacogenetics. Ther. Drug Monit. 1993; 15: 224-235.
16. Lemoine A, Gautier JC, Azoucy D et al. Major pathway of imipramine metabolism is catalyzed by cytochrome P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 1993; 43: 827-832.
17. Ohmori S, Takeda S, Kitada M, Rikihisa T, Kikuchi M, Nakakubo Y. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol. Pharm. Bull. 1993; 16: 571.
18. Glassman AH, Perel JM, Shostak M. Clinical implications of imipramine plasma levels for depressed illness. Arch. Gen. Psychiat. 1977; 34: 197-204.
19. Reisby N, Gram LF, Bech P et al. Imipramine: Clinical effects and pharmacokinetic variability. Psychopharmacology. 1977; 54: 263-272.
20. Kantor SJ, Glasmman AH, Bigger JT Jr. The cardiac effects of therapeutic plasma concentrations of imipramine. Am. J. Psychiat. 1978; 135: 534-537.
21. Tanaka T, Morinobu S, Kawakatsu S et al. Measurement of imipramine metabolic ratio and influence of imipramine metabolism on clinical effects. Ann. Res. Pharmacopsychiat. Res. Found. 1993; 24: 179-186 (in Japanese).
22. Spina E, Pollicmo AM, Avenosos A, Campo GM, Perucca E, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int. J. Clin. Pharmacol. Res. 1993; 13: 167-171.
23. Perucca E, Gantti G, Cipolla G et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin. Pharmacol. Ther. 1994; 56: 471-476.
24. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 1996; 51: 73-78.
25. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RH. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 1992 34: 262-265.
26. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin. Invest. 1993; 71: 1002-1009.
27. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiat. 1996; 153: 311-320.
28. Taylor D. Selective serotonin reuptake inhibitors and tricyclic anti-depressants m combination. Interactions and therapeutic uses. Br. J. Psychiat. 1995; 167: 575-580.
29. Brosen K and Gram LF. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 1988; 43: 400-406.
30. Breyer-Pfaff U, Pfandle B, Nill K et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin. Pharmacol. Ther. 1992; 52: 350-358.
31. Koyama E, Sohn DR, Shin SG et al. Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol a-hydroxylation and S-mephenytoin 4-hydroxylation phenotypes. J. Pharmacol. Exp. Ther. 1994; 271: 860-867.
32. Skjelbo E, Brosen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphysm is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 1991; 49: 18-23.
33. Nielsen KK, Brosen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: Relationship to the spartine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther. 1994; 55: 518-527.